170727-03-4

Basic information

• Product Name: Carbamic acid, [4-[(hydroxyimino)methyl]phenyl]-, 1,1-dimethylethyl ester
• CAS NO: 170727-03-4
• Molecular Formula: C12H16N2O3
• Molecular Weight: 236.271
• Mol File: 170727-03-4.mol

Chemical Properties

• CAS DataBase Reference: Carbamic acid, [4-[(hydroxyimino)methyl]phenyl]-, 1,1-dimethylethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Carbamic acid, [4-[(hydroxyimino)methyl]phenyl]-, 1,1-dimethylethyl ester(170727-03-4)
• EPA Substance Registry System: Carbamic acid, [4-[(hydroxyimino)methyl]phenyl]-, 1,1-dimethylethyl ester(170727-03-4)

Safety Data

• Hazardous Substances Data: 170727-03-4(Hazardous Substances Data)

Upstream product

• 144072-30-0 4-((tert-butoxycarbonyl)amino)benzaldehyde 

Downstream Products

• 1181214-92-5 {4-[5-(4-Trifluoromethylphenyl)-4,5-dihydro-isoxazol-3-yl]-phenyl}-carbamic acid tert-butyl ester 
• 1181214-91-4 4-[5-(4-trifluoromethylphenyl)-4,5-dihydro-isoxazol-3-yl]-phenylamine 
• 190447-74-6 C₃₁H₄₆N₆O₁₀ 
• 190447-73-5 (S)-2-Butoxycarbonylamino-3-{2-[3-(4-tert-butoxycarbonylamino-phenyl)-4,5-dihydro-isoxazol-5-yl]-acetylamino}-propionic acid methyl ester 
• 190447-72-4 [3-(4-tert-Butoxycarbonylamino-phenyl)-4,5-dihydro-isoxazol-5-yl]-acetic acid butyl ester 
• 170726-74-6 [3-[(4-t-butyloxycarbonylamino)-phenyl]isoxazolin-5-yl]acetic acid 
• 190446-52-7 4-(tert-butoxycarbonylamino)benzohydroximinoyl chloride 

Relevant articles and documents

Isoxazole-containing thiourea inhibitors useful for treatment of varicella zoster virus

This Invention provides a compound of the Formula: wherein X is R1, R2, R3 and R4 are described in the specification and a pharmaceutical composition comprising the compound used for inhibiting replication of a

Discovery of an orally active series of isoxazoline glycoprotein IIb/IIIa antagonists

Using isoxazoline XR299 (la) as a starting point for the design of highly potent, long-duration GPIIb/IIIa antagonists, the effect of placing lipophilic substituents at positions α and β to the carboxylate moiety was evaluated. Of the compounds studied, it was found that the n-butyl carbamate 24u1,2 exhibited superior potency and duration of ex vivo antiplatelet effects in dogs. Replacement of the benzamidin-4-yl moiety with alternative basic groups, elimination of the isoxazoline stereocenter, and reversal of the orientation of the isoxazoline ring resulted in lowered potency and/or duration of action.